The research, published in BMC Pediatrics, followed 81 patients aged 1 to 18 years over a six-month period. The cohort included 36 children with maple syrup urine disease, a disorder of branched-chain amino acid metabolism; 30 with methylmalonic or propionic acidemia, two related organic acidemias; 6 with isovaleric acidemia; and 9 with urea cycle disorders, which impair the body’s ability to convert waste nitrogen into urea for excretion. At the start of the study and again six months later, the team collected detailed anthropometric measurements, three-day dietary records analyzed with the BeBiS 8.2 nutrition software, and plasma amino acid profiles, alongside metabolic control parameters such as ammonia levels and acid-base status drawn from patient files.

The headline finding is sobering. Among children with maple syrup urine disease, 47.2 percent were stunted and 36 percent were underweight at baseline, and six months later the figures remained essentially unchanged at 44.4 percent and 52.2 percent respectively. In the methylmalonic and propionic acidemia group, the situation actually worsened over the study window: the prevalence of underweight rose from 34.8 percent to 43.5 percent, while stunting climbed from 43.3 percent to 50 percent. Children with urea cycle disorders showed persistent stunting at a rate of 44.4 percent. Only the small isovaleric acidemia group maintained normal growth, a bright spot the authors note with caution given the limited number of patients involved.

What makes these numbers particularly troubling is that they occurred despite what appears, on paper, to be adequate nutrition. Total protein intake in the cohort met disease-specific guideline recommendations, and the protein-to-energy ratio, a key metric in metabolic dietetics that describes how much protein is delivered relative to total caloric intake, fell within recommended ranges. Yet when the researchers dissected the composition of that protein, a different picture emerged. Natural protein from ordinary foods remained insufficient across the groups, and in children with maple syrup urine disease, synthetic amino acid mixtures supplied up to 75 percent of total protein intake. These medical formulas, stripped of the amino acids the patients cannot metabolize, are the backbone of treatment, but the study suggests that heavy reliance on them may come at a cost.

That cost shows up in the blood. Chronic deficiencies of the essential amino acids isoleucine and valine were prominent in patients with maple syrup urine disease and in those with methylmalonic and propionic acidemia. This is a known hazard of amino acid therapy: because the synthetic mixtures must exclude or severely limit the offending amino acids, patients can easily tip into deficiency of other essential amino acids if the formulation and natural protein allowance are not finely tuned. Isoleucine and valine are indispensable for protein synthesis, and chronically low plasma levels could plausibly constrain linear growth, muscle development, and overall nutritional status in growing children.

Dietary quality beyond protein also emerged as a consistent weakness. Intake of polyunsaturated fatty acids, the omega-3 and omega-6 fats critical for brain development and inflammatory regulation, was inadequate in every disease group, as was dietary fiber. Restricted diets naturally limit food variety, and children who consume large fractions of their nutrition as formula often miss out on the whole grains, seeds, nuts, and oily fish that supply these micronutrients and macronutrients in a typical diet. The researchers suggest that this suboptimal dietary quality may be another contributing factor to the poor growth outcomes they documented.

One of the most intriguing results concerns acid-base status. In children with methylmalonic and propionic acidemia, blood pH showed a positive correlation with height-for-age Z-score, with a correlation coefficient of 0.410 and a p-value below 0.05. In plain terms, children whose blood was less acidic tended to be taller for their age. Organic acidemias are characterized by recurrent episodes of metabolic acidosis, in which acidic metabolites accumulate and lower blood pH, and chronic or repeated acidosis is known from other clinical contexts to suppress growth hormone signaling and bone mineralization. While a correlation cannot prove causation, the finding hints that more aggressive control of acid-base balance might be an underappreciated lever for improving growth in these patients. Notably, the protein-to-energy ratio showed no association with height-for-age Z-scores, suggesting that simply adjusting macronutrient proportions may not be enough to rescue growth.

The study also exposes a gap in the clinical infrastructure supporting these families. The authors found substantial variability among current disease-specific dietary guidelines, meaning that children with the same diagnosis may receive meaningfully different nutritional prescriptions depending on which protocol their center follows. For ultra-rare diseases where evidence is scarce and guidelines are often built on expert consensus rather than controlled trials, this inconsistency is understandable but consequential. The researchers argue that their findings underscore the need for standardized, evidence-based nutritional protocols developed through multi-center collaboration.

Methodologically, the study has both strengths and limitations worth noting. Its prospective design, with standardized anthropometry, dietary records, and plasma amino acid measurements at two time points, is more rigorous than the retrospective chart reviews that dominate the rare disease literature. The statistical approach, using Wilcoxon tests for paired comparisons and Spearman correlations for associations, is appropriate for the non-normally distributed data typical of nutritional studies. On the other hand, the six-month follow-up is short for assessing linear growth, which unfolds over years, and the small size of the isovaleric acidemia and urea cycle disorder subgroups limits the precision of conclusions for those diagnoses. The study was approved by the ethics committee of Gaziantep University Faculty of Medicine, with written informed consent obtained from participants and their parents, and it received no external funding.

For clinicians and families, the practical message is that growth impairment in organic acidemias and urea cycle disorders is not a sign of dietary non-compliance but a signal that current therapeutic strategies may be inherently insufficient. The authors call for close monitoring by a multidisciplinary metabolic team, including physicians, dietitians, and nurses, with attention to optimizing natural protein tolerance, correcting essential amino acid imbalances, supplementing polyunsaturated fatty acids and fiber, and vigilantly managing acid-base status. As newborn screening programs expand and more children with these disorders survive into adolescence and adulthood, the question of how to help them not just survive but thrive is becoming one of the defining challenges in the field of inherited metabolic disease.

Subject of Research: Dietary intake, metabolic control, and growth outcomes in children with organic acidemias and urea cycle disorders

Article Title: Dietary intake, metabolic control and growth in patients with organic acidemia and urea cycle disorders

Article References: Kumru Akin, B., Köşeci, B., Çiçek Türköz, E., Onenli Mungan, H. N., Keskin, M., & Gökmen Ozel, H. (2026). Dietary intake, metabolic control and growth in patients with organic acidemia and urea cycle disorders. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07722-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07722-5

Keywords: organic acidemia, urea cycle disorder, maple syrup urine disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, dietary protein restriction, amino acid mixtures, stunting, metabolic acidosis, pediatric nutrition, growth impairment

The therapeutic landscape has changed dramatically over the past several years. Treatment options now span substrate reduction and replacement, cofactor replacement, enzyme replacement, RNA-based therapies, cell therapy, gene therapy, and gene editing. The general trend, Whitehead notes, is a movement away from ongoing metabolic replacement strategies such as dietary modification, cofactor supplementation, and enzyme replacement therapy toward single-instance genetic interventions like gene therapy and, eventually, gene editing. To keep pace with this rapidly evolving field, clinicians can consult a dynamic, continuously updated resource known as the Metabolic Treatabolome, which catalogs treatable inherited metabolic disorders. For the practicing radiologist, however, the essential message is simpler: certain reproducible patterns on MRI and MR spectroscopy should trigger immediate consideration of a treatable neurogenetic condition, because these diseases arise from selective tissue vulnerability that produces identifiable and characteristic imaging signatures.

The first challenge is knowing when to suspect a metabolic disorder at all. The imaging characteristics of neurogenetic brain diseases often overlap with far more common entities, particularly hypoxic-ischemic injury and encephalitis. Profound hypoxic-ischemic injury in neonates typically affects the posterior putamen, the posterior limb of the internal capsule, and the ventrolateral thalamus simultaneously, because these regions have high energy demands. When patterns diverge from this expectation, metabolic disease should rise on the differential. Specific red flags include deep gray nuclear lesions that spare the thalami or basal ganglia, temporally disparate lesions, brainstem-predominant abnormalities, unexplained reduction in brain volume, malformations, and chronic lesions in a newborn, none of which fit the typical timeline or distribution of oxygen deprivation or infection.

Among the white matter-dominant disorders, X-linked adrenoleukodystrophy stands out as the single most important diagnosis to know. Caused by variants in the ABCD1 gene, a peroxisomal defect, it is the most common leukodystrophy, it is treatable, and it shows a moderately specific imaging pattern: in roughly 80 percent of cases, demyelination begins in the splenium of the corpus callosum, spreads to the forceps major, descends along projection fibers, and ultimately involves auditory and visual white matter tracts. Active inflammation is marked by reduced diffusivity and contrast enhancement. Alternative phenotypes include frontal onset, deep diffuse, and projectional patterns. With the addition of ABCD1 to the recommended uniform screening panel in the United States, 47 states and the District of Columbia now perform newborn screening, and MRI surveillance identifies the fewer than half of affected boys who develop the cerebral form. Treatment, most effective early when few brain lesions exist, is allogeneic hematopoietic stem cell transplantation, with autologous gene-modified stem cell transplant as a second-line option. Patients with typical lesions and a Loes score below 10 may qualify for therapy, and post-treatment stability is defined as a Loes score below 10 or an increase of less than 6 points from baseline.

Two other leukodystrophies, Krabbe disease and metachromatic leukodystrophy, illustrate how clinical context and subtle imaging distinctions guide diagnosis. Juvenile-onset Krabbe disease can closely mimic X-linked adrenoleukodystrophy with poorly marginated splenial and forceps major abnormality, while the infantile form looks different, featuring lesions in the dentate nuclear hilus, deep cerebral hyperattenuation on CT from galactosylceramide deposition, thalamic T2 shortening, optic chiasm thickening, and enhancement of cranial nerves and the cauda equina. A striated, tigroid pattern in the corona radiata from perivascular myelin sparing is typical but not specific. Hematopoietic stem cell transplant works best before symptoms appear, ideally in the first month of life, which makes newborn screening for GALC enzyme activity, now implemented in 18 states, critically important. Metachromatic leukodystrophy shares several features with infantile Krabbe disease but usually spares the chiasm and hindbrain, may involve the genu earlier, and lacks the deep cerebral hyperattenuation. Markedly elevated myoinositol on spectroscopy and gallbladder disease, even in pre-symptomatic patients, provide additional clues. The preferred treatment is gene therapy using lentivirally modified ARSA, available for children under seven who are pre-symptomatic or only mildly symptomatic, and six states have added MLD to newborn screening panels since its endorsement.

Maple syrup urine disease demonstrates how imaging can track treatment response in real time. This aminoacidopathy typically presents at the end of the first neonatal week with encephalopathy and striking white matter edema, with symmetric, markedly reduced diffusivity and swelling in myelinating and myelinated tracts of the cerebrum, cerebellum, and brainstem. Spectroscopy reveals elevated branched-chain amino acids and ketoacids as a broad doublet near 0.9 to 1 ppm, though detecting these peaks reliably at 3 tesla requires careful echo time selection due to anomalous J-coupling. While protein restriction is necessary and leucine, isoleucine, and valine cannot be eliminated entirely from the diet, liver transplantation is considered a definitive treatment that permits a more relaxed diet. A favorable post-transplant scan shows resolution of the diffusion abnormalities and intramyelinic edema, resolution of lactate, normalization of NAA, and reduction of the branched-chain amino acid peaks, findings documented in a patient imaged seven years after curative transplantation. The mucopolysaccharidoses, a group of multi-system lysosomal storage disorders, offer another treatable example: enlarged perivascular spaces combined with skeletal changes such as a J-shaped sella, frontal bossing, and odontoid hypoplasia suggest the diagnosis, and weekly enzyme replacement therapy has been shown to resolve white matter signal abnormality and stabilize neurological symptoms in eligible patients.

Menkes disease, an X-linked copper transport disorder caused by ATP7A variants, produces one of the most visually distinctive findings in pediatric neuroradiology: diffuse marked elongation and tortuosity of the intracranial arteries, present almost always, even in neonates, because copper is essential for vessel wall integrity. Supporting findings include delayed myelination, transient tumefactive temporal lobe vasogenic edema between one and ten months of life, basal ganglia lesions with reduced diffusion, and skeletal changes such as Wormian bones and fractures. Early daily subcutaneous copper histidinate injections, which bypass the defective copper transporter, are essential for preventing severe neurodegeneration, reducing seizures, and prolonging life. On the gray matter side, Wilson disease from ATP7B variants shows basal ganglia, thalamic, midbrain, and pontine lesions with a characteristic mixed increased-and-decreased signal, where T2 signal correlates with neurological dysfunction and T1 signal with hepatic dysfunction, and the famous face of the giant panda in the midbrain may appear. Copper reduction through diet, zinc supplementation, and chelation, or curative liver transplantation, addresses the underlying metabolic derangement.

Several other gray matter disorders reward pattern recognition. Biotin-thiamine-responsive basal ganglia disease, from SLC19A3 variants, causes thalamic and cortical edema with prominent putaminal involvement, and responds, as its name promises, to lifelong biotin and thiamine supplementation. Glutaric aciduria type 1 announces itself structurally before the basal ganglia lesions appear, with underopercularization and enlarged temporopolar subarachnoid spaces, and early l-carnitine with an arginine-restricted, lysine-free diet is highly effective at preventing permanent striatal injury. Urea cycle defects produce hyperammonemic brain injury with peri-insular and deep cortical lesions that spare the thalami, a pattern unusual in hypoxic-ischemic injury, alongside elevated glutamine and glutamate with reduced myoinositol on spectroscopy; dietary management and, in neonatal-onset ornithine transcarbamylase deficiency, curative liver transplantation are the mainstays. Molybdenum cofactor deficiency type A responds to substrate replacement with cyclic pyranopterin monophosphate, and neuronal ceroid lipofuscinosis CLN2, the most common childhood neurodegenerative disease group, can be slowed by bi-weekly intraventricular cerliponase alfa, identifiable on imaging by cerebellar-predominant atrophy, thalamic T2 shortening, and subinsular signal change.

Finally, MR spectroscopy deserves special emphasis because it can be diagnostic even when the MRI appears entirely normal. Fatty acid metabolism disorders such as CPT1 deficiency produce elevated lipid peaks at 0.9 and 1.3 ppm on a normal-appearing scan, and respond to dietary modification with frequent high-carbohydrate meals and medium-chain fatty acid supplementation. Galactosemia yields a large doublet at 3.7 ppm from toxic galactitol accumulation, which inverts at intermediate echo times and normalizes with dietary change. Cerebral creatine deficiency syndromes show markedly reduced creatine peaks at 3 and 3.95 ppm, and creatine supplementation can normalize the spectrum in AGAT and GAMT deficiency. The review recommends a low threshold for adding short-echo single-voxel spectroscopy to any suspected neurometabolic case, with the voxel placed in the deep gray nuclei for poliodystrophies and parietal white matter for suspected leukodystrophies. The overarching conclusion is unambiguous: symmetric gray or white matter lesions in patterns atypical for hypoxic-ischemic injury and infection, or a characteristic spectroscopic signature, should prompt consideration of these not-to-be-missed disorders, because failure to recognize them promptly delays lifesaving and morbidity-reducing treatment.

Subject of Research: Neuroimaging patterns of treatable neurogenetic and inherited metabolic brain diseases in children

Article Title: Don’t miss this treatable neurogenetic disease!

Article References: Whitehead, M. T. (2026). Don’t miss this treatable neurogenetic disease!. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06796-8

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06796-8

Keywords: neurogenetic diseases, leukodystrophy, MRI, MR spectroscopy, X-linked adrenoleukodystrophy, Krabbe disease, metachromatic leukodystrophy, maple syrup urine disease, Wilson disease, newborn screening, gene therapy, pediatric neuroradiology